Christopher Aker - 20 May 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RGLS	Stock Option (Right to Buy)	Award	$0	+363,000		$0.000000	363,000	20 May 2024	Common Stock	363,000	$2.01	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.